Compare ULH & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | PRME |
|---|---|---|
| Founded | 1932 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.9M | 526.0M |
| IPO Year | 2004 | 2022 |
| Metric | ULH | PRME |
|---|---|---|
| Price | $17.91 | $3.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $7.11 |
| AVG Volume (30 Days) | 48.1K | ★ 3.0M |
| Earning Date | 10-22-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,461,708,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $90.67 |
| Revenue Next Year | $4.75 | $19.46 |
| P/E Ratio | $20.59 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $11.73 | $2.67 |
| 52 Week High | $25.80 | $6.85 |
| Indicator | ULH | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 50.31 |
| Support Level | $14.82 | $3.14 |
| Resistance Level | $19.07 | $3.56 |
| Average True Range (ATR) | 0.90 | 0.25 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 55.52 | 55.35 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.